Skip to main content

Table 3 Association of the CTGF promoter polymorphism at -945 with clinical outcomes at follow-up

From: The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes

   

CC (%)

CG (%)

GG (%)

Total (%)

P-value

Diabetic nephropathy

Mortality

Yes

42 (30)

62 (44)

36 (26)

140 (100)

0.369

  

No

84 (27)

158 (51)

66 (22)

308 (100)

 
 

Cardiovascular (CV) death

Yes

20 (27)

35 (48)

18 (25)

73 (100)

0.915

  

No

106 (28)

185 (49)

84 (23)

375 (100)

 
 

Non-fatal CV event

Yes

40 (35)

50 (43)

25 (22)

115 (100)

0.173

  

No

86 (26)

170 (51)

77 (23)

333 (100)

 
 

End-stage renal failure

Yes

29 (30)

46 (47)

23 (23)

98 (100)

0.886

  

No

97 (28)

174 (50)

79 (22)

350 (100)

 

Normoalbuminuria

Mortality

Yes

14 (40)

15 (43)

6 (17)

35 (100)

0.394

  

No

112 (29)

186 (48)

86 (22)

384 (100)

 
 

Cardiovascular (CV) death

Yes

4 (31)

6 (46)

3 (23)

13 (100)

0.991

  

No

122 (30)

195 (48)

89 (22)

406 (100)

 
 

Non-fatal CV event

Yes

15 (37)

20 (49)

6 (14)

41 (100)

0.415

  

No

111 (29)

181 (48)

86 (23)

378 (100)

 
 

Microalbuminuria

Yes

21 (38)

25 (45)

9 (16)

55 (100)

0.306

  

No

105 (29)

176 (48)

83 (23)

364 (100)

 
 

Development of nephropathy

Yes

0 (0)

1 (100)

0 (0)

1 (100)

0.581

  

No

126 (30)

200 (48)

92 (22)

418 (100)

 
  1. There is no effect of the -945GG genotype on either mortality, fatal or non-fatal cardiovascular events, or development of renal disease. P-values are calculated using Fisher's exact test.